The FDA approval for extending the shelf life of a key product directly impacts Cerus Corporation's operational efficiency and customer satisfaction. This regulatory milestone is likely to be viewed positively by investors, as it demonstrates the company's ability to navigate regulatory processes and improve its product offerings. The extension can lead to cost savings for customers and potentially increase demand for the INTERCEPT Platelet Processing Sets, thus positively impacting Cerus's financial performance in the short term.